Phase 2 results announced for sofosbuvir-based regimens in hepatitis C patients before and after liver transplantation

Gilead Sciences, Inc. (Nasdaq: GILD) has announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the once-daily nucleotide analogue inhibitor sofosbuvir plus ribavirin (RBV) for both the prevention and treatment of recurrent chronic hepatitis C virus (HCV) infection among patients who undergo liver transplantation. The findings will be presented this week at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington, D.C...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/rGABYxVH7yQ/268346.php

sport medical sport news news